

Euro Rates Strategy

S&P Lowers France to AA Stable – Market Implications

- **S&P downgrades France:** S&P lowered its rating of France from AA+ Negative Outlook to AA Stable this morning. S&P said the downgrade reflects the view that the French government's economic policies are unlikely to substantially raise France's medium-term growth prospects and that lower economic growth is constraining the government's ability to consolidate public finances.
- **Limited market reaction:** France was already on Negative Outlook which signified prospects for a downgrade over the medium term. The market reaction this morning has been limited (around 2bp wider in the 10yr sector to Germany) and the rating puts France more in line with the EGB credit curve. We do not see this rating action as a significant market event for EMU spreads.
- **France has various market supports:** The rating change reflects an economic reality that the market had more or less already discounted. The more dominant drivers for the OAT sector – and EMU more broadly – remain ECB policy. This is likely to remain supportive and we continue see the market depth and liquidity of France as a key strength in attracting demand. Recent flows also indicate net buying of France over recent weeks.
- **OAT vs Bunds and OLOs:** France has traded well over 2013, with 10yr OAT-Bund spreads now around 50bp. The rating action lends support to the notion that further spread tightening looks limited from current levels. We recommend selling 5yr OATs vs Bunds and OLOs (via a butterfly trade).
- **Continue to prefer SSA-OAT trades:** We continue to see good relative value between core German and Dutch agencies vs France, although entry points have been better. In addition, supranationals such as the EU and EIB continue to look appealing vs OATs in the belly of the curves.
- **Implications for other SSA ratings:** French agencies are likely to have their ratings normalized to S&P's rating of France given the strong connection to the sovereign (EPIC status). The EIB is rated AAA stable and the EU AAA negative outlook and we do not see a rating action on such supras as a necessary or mechanical outcome from S&P's move on France. The EFSF may be impacted (note that it was impacted when S&P downgraded France back in January 2012). However, we do not think this would significantly impact spreads and we continue to see the EFSF as a core, liquid market issuer within the SSA space.

Peter Goves
+44-20-7986-3215
peter.goves@citi.com

Nishay Patel
+44-20-7986-1007
nishay.patel@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

France lowered to AA Stable by S&P

The rating drivers

Drivers: S&P this morning lowered its long-term rating of France to AA. The outlook is now stable signifying that there is low likelihood of further rating actions anytime soon. The drivers behind S&P's decision included:

- Reforms in the product, labour and services market are positive, but unlikely to “substantially raise France’s medium term growth prospects, and that ongoing high unemployment is weakening support for further significant fiscal and structure policy measures”.
- “...lower economic growth is constraining the government’s ability to consolidate public finances”.

S&P’s expectations: In addition, S&P states that “political room for additional revenue measures has lessened”. In their opinion, France’s current fundamentals and S&P’s expectation for how they will evolve, warrant a stable outlook according to their criteria. That is to say, inter alia, they expect the following:

- Continued government commitment to reform
- Net general government debt peaking around 86% in 2015
- Close to zero growth this year and average growth of 1% for 2014-2015
- General government deficit of 4.1% of GDP in 2013 (in line with government’s target)


No further rating action likely over the medium term: This is the context S&P views France in and a significant (positive or negative) deviation away from this is the sort of driver that would prompt a re-appraisal. Given the stable outlook, we do not envisage any further rating action by S&P regarding France over the medium term.

EMU market implications

(1) Limited market reaction – France was already on negative outlook

Today’s action by S&P is not a significant market moving event in our view. In one sense, France is now better in line with an ordinal ranking of EMU credit ratings and 10yr yields (Figure 1).

Figure 1. EMU yields vs Blended Rating Score



Source: Citi Research, S&P, Moody's, DBRS, Fitch

Market reaction: On the market open, France was around 1bp wider to Germany in the 5yr sector, and 2bp wider in the 10yr sector. This is not dramatic we do not anticipate a re-pricing of France based on this rating action.


Rating affirms what the market has already discounted: The move to AA stable is a reflection of the economic reality that is already widely appreciated. France was already on negative outlook and on several occasions, S&P had stated that “*the outlook on France is negative, indicating that we believe that there is at least a one-in-three chance that we could lower the ratings during 2013*” (S&P Research Update 23rd November 2012). Furthermore, a loss of the AAA standard probably has more psychological importance for the market than intra-Investment Grade rating changes. The reaction this morning further supports this view.

(2) France has various market supports

ECB policy: As stated, intra-Investment Grade rating changes tend not to be significant spread drivers. Other factors are much more significant for assessing investment decisions in OATs, not least ECB policy. The surprise decision to cut the refi rate yesterday is a support to all EMU markets, especially the core ([European Rates Weekly](#)). Furthermore, a further LTRO next year would also provide impetus for a broad-base spread tightening ([Global Economic Outlook and Strategy](#)).


Demand and flows: We continue to see France as the main and important liquid core bond market alternative to Germany. The rating action supports the notion that 10yr OAT-Bund spreads tightening from current levels (~50bp) is probably limited. The last few weeks have seen demand for France¹ (Figure 3). Net demand for France over a four week period has now moved to positive territory (Figure 4). On a more micro level, demand has been concentrate in 2-5yrs and 5-10yrs over the last few weeks (Figure 5). More broadly, anecdotal evidence also indicates that OATs remain the key alternative to Bunds by Asian accounts and the domestic buyer base is and will likely remain an important contributor to the overall demands structure.

Figure 2. France performance vs Germany




Source: Citi Research

Figure 3. Weekly net DV01




Source: Citi Research

Figure 4. France: Net DV01 across all sectors



Source: Citi Research

Figure 5. France: Net DV01 of sectors



Source: Citi Research

Trading strategies

OAT-OLO spreads and OAT-Bund spreads

Going forward, we would expect renewed interest in EGB carry trades to be more favourable for Belgium than France until year-end. This is based on the slightly better carry profile (for Belgium) and the fact that there is minimal Belgian supply remaining this year. We therefore recommend holding onto 5yr Belgium vs France positions targeting a further 4bps of widening from current levels.

¹ Based on electronically executed flows with Citi

- **Remain overweight OLO Mar18 vs OAT Apr18** ([Belgium - strategy recommendations](#))

- Open 19.5bp. Current 14bp. Target 10bp. Stop 25bp

Over the medium-term, we expect OAT-Bund spreads to widen by 20bps over the next 6months due to a non-supportive cash flow profile in 2014, diverging fundamentals and our expectations of an imbalance between supply and demand in 1H14. Further details can be found in [European Rates Weekly](#)

5yr Bunds-OAT-OLO butterfly

Prior to yesterday's ECB meeting (where we did not expect a rate cut) we recommended selling 5yr OATs vs Bunds² on a tactical basis due to the attractive entry level (tight spreads and we are currently at levels where spreads have previously widened) and the prospect of there being some concession in the lead up to the next BTAN supply on 21 November. Furthermore, the cash flows profile is strongly non-supportive for OATs into year-end due to the absence of coupons and redemptions. Although the yield spread is unchanged since our recommendation we feel the risk-reward of this trade has reduced slightly.

Our preferred trading strategy (one with a better risk-reward, in our view) is still to be short 5yr OATs vs Bunds but to add a long OLO position to this structure. This enables the structure to have a slightly better carry profile and provides a slight reduction in risk (to the short OAT vs Bund leg) should investors look to extend along the credit curve. Furthermore, the entry level is still attractive.

Below we highlight two trades that investors may wish to consider. The net carry on these trades is virtually flat (only 1bp against you on a 3month horizon).

■ Sell BTAN 1.75% Feb17 vs OLO 4% Mar17 and Bobl 0.5% Apr17

- Current/Open 6bp. Target 16bp. Stop 1bp

■ Sell OAT 4.25% Oct17 vs OLO 5.5% Sep17 and Bobl 0.5% Oct17


- Current/Open 18bp. Target 29bp. Stop 13bp

Figure 6. OLO 4% Mar17, BTAN 1.75% Feb17, Bobl 0.5% Apr17 yield fly



Source: Citi Research

Figure 7. OLO 5.5% Sep17, OAT 4.25% Oct17, Bobl 0.5% Oct17 yield fly






Source: Citi Research

² 5yr Bund-OAT trade, 6 Nov 13

Appendix: Relative value

The chart below shows the richest and cheapest French bonds across the curve vs a fitted yield curve and swaps. As show in the table below,

Figure 8. France: richest and cheapest bonds vs a fitted yield curve and swap curve (based on a 6month horizon and minimum maturity of 2yrs)

Versus Fitted Yield Curve							Versus Swap Curve (CAS)						
FRANCE	Richest		Rank	Issued	Size (€bn)	ZScore	Richest		Rank	Issued	Size (€bn)	ZScore	
		1	5.00 Oct16	29	-1.95	Oct00	1		3.00 Apr22	33	-1.48	Feb12	
		2	3.75 Apr17	35	-1.86	Apr06	2		3.25 Oct21	35	-1.39	Oct10	
		3	1.75 Feb17	20	-1.85	Feb11	3		2.25 Oct22	24	-1.35	Oct11	
		4	4.75 Apr35	21	-1.77	Apr03	4		5.00 Oct16	29	-1.35	Oct00	
		5	4.25 Oct17	28	-1.69	Oct06	5		3.75 Apr21	34	-1.34	Apr05	
		5	3.50 Apr20	36	0.87	Feb10	5	3.75 Oct19	32	-0.51	Oct08		
		4	3.25 May45 (30y)	9	1.10	May12	4	0.25 Nov15 (2y)	21	-0.26	Nov12		
		3	3.50 Apr26	30	1.16	Apr10	3	2.25 Feb16	29	-0.16	Feb10		
		2	1.00 Nov18 (5y)	17	1.58	Nov12	2	1.00 Nov18 (5y)	17	-0.16	Nov12		
		1	3.75 Oct19	32	2.07	Oct08	1	2.25 May24	4	0.00	Nov13		

Source: Citi Research


SSA market implications

(1) Relative value and SSA-OAT trading strategies

Agencies: We have recently detailed trading strategies in being long certain SSAs vs France. In particular, spreads between 5yr KfW and France have tightened since we detailed the relative value in our [Euro SSA and Covered Bond Monthly](#). Across the curve, spreads between KfW and France have moved around 4bp-5bp over the last week making entry points now less attractive (Figure 9). A similar theme is apparent in Dutch agency spreads vs France.


Supranationals: We continue to see good relative value between supranationals such as the EIB and EU vs France. Switches into supras and out of France can still be made at a flat spread or even a small pick-up (Figure 10). They also remain near the wide end of recent trading ranges. Further details can be found in our [Strategies for trading supranationals](#).

Figure 9. KfW has rallied vs France over the last week



Source: Citi Research

Figure 10. EIB's spread curve to France (bp)



Source: Citi Research

Figure 11. What happened when France was last downgraded by S&P in Jan 2012

	S&P Rating	January Report Date
France	AA+ Neg ↓	13-Jan-12
EFSF	AA+ Neg ↓	16-Jan-12
EIB	AAA Neg	16-Jan-12
CADES	AA+ Neg ↓	17-Jan-12
KfW	AAA Stable	17-Jan-12
EU	AAA Neg	20-Jan-12

Source: Citi Research, S&P, Bloomberg.


(2) Implications for other SSA ratings

A key question the downgrade of France poses is what it might mean for other issuers within the SSA space, both in terms of direct rating changes and spread implications for the market. The connection between France and SSAs differs depending on the fundamental characteristics of the guarantee in question. We can also take a look at what S&P did the last time France was downgraded back in January 2012. Here, within days, the EFSF and CADES had their ratings normalized, but at the time, the AAA ratings of EIB and EU were affirmed (Figure 11). As S&P stated when it normalized the rating of CADES in January 2012, *"Under our methodology applicable to government-related entities (GREs), we equalize the ratings on GREs with their related sovereign when we believe there is an 'almost certain' likelihood that they would receive timely and sufficient extraordinary support from that sovereign."*³

We briefly review the various sectors in turn below. In general, we not think rating changes will lead to significant re-pricing within the sector at large

French agencies: The closest SSA sector associated with France is its agency sector. However, note that the largest issuer in this space – CADES – is no longer rated by S&P. The last research update by S&P was in February 2013 where the rating was affirmed at AA+ negative outlook, but then withdrawn because S&P *"chose not to continue ratings surveillance on an unsolicited basis"*. At the time, S&P equalized the rating of CADES to France due to the critical and integral link the agency has to the sovereign. Due to the EPIC status French agencies generally enjoy, we would expect ratings of French agencies to be normalized to AA for those rated by S&P. We would not expect this to affect secondary market levels significantly and continue to expect French agencies to trade generally tight to the sovereign. For more details, see our [French agencies and covered bonds in focus](#).

Figure 12. EU and EIB Rating Distribution



Source: Citi Research

EU: The EU is rated AAA negative outlook by S&P and due to fundamental characteristics (for example its low level of debt, strong legal framework), we do not think a downgrade of the EU is mechanical fall out due to the move on France. Specifically, in their last summary on the EU (4th December 2012), S&P stated *"The negative outlook reflects our view that there is at least a one-in-three chance that we could lower the rating by 2014. Downward rating pressure could build if we were to downgrade a 'AAA' rated EU member (currently these are Denmark, Finland, Germany, Luxembourg, Netherlands, Sweden, and the U.K.) or should there be further deterioration in the overall creditworthiness of its 27 members."*

EIB: The EIB is rated AAA stable by S&P – having recently had its own "negative outlook" removed on 22nd October following the €10bn increase in its paid-in capital. It has the support of 28 EU member states, good asset quality and strong legal and market franchise. Its stable outlook reflects the low chance of a rating change over the medium term.

EFSF: The EFSF was downgraded shortly after the downgrade of France to AA+ by S&P back in January 2012. For various reasons, its rating is more closely connected to large guarantors within its structure. We would not be surprised if the EFSF had its rating normalized to France based on what S&P have previously indicated, although again this is not certain and not altogether "mechanical". However, we believe the market impact from this would be limited and we would still see the EFSF as a core market and liquid issuer within the SSA space. Specifically, in their last Summary (December 2012), S&P stated that:

³ S&P "Rating Actions Taken on 25 Eurozone Government Related Entities Following Sovereign Actions" 19th January 2012.

The negative outlook on the EFSF mirrors the outlook on the 'AA+' rated sovereign guarantors, the Republic of France and Austria. This is based on our weakest-link approach, equalizing our issuer credit rating on the EFSF with the long-term foreign currency rating on the highest rated guarantors (plus liquid securities held by the EFSF) that allow full coverage of the EFSF's effective maximum borrowing capacity approved by member states.

We could lower the rating if we were to downgrade any of the currently 'AA+' or 'AAA' rated guarantors to 'AA' or below.

Conclusion

The one notch downgrade by S&P to AA Stable is not a significant market event in our view. The market reaction has been limited and we continue to see various supports for the OAT market in general. ECB policy clearly remains accommodative and Citi's base case is for another LTRO next year.

In terms of trading strategies, the rating action lends support to the notion that further spread tightening of OAT-Bund spreads looks limited from current levels. We recommend selling 5yr OATs vs Bunds and OLOs (via a butterfly trade). Within the SSA space we continue to see relative value between core agencies and supras vs France. Related rating actions in the French SSA sector should not be altogether surprising and in general, we do not expect this to cause a significant disturbance in secondary market spreads.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Belgium, France.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Belgium, Germany, France.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Germany, France.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Belgium, Germany, France in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): Belgium, Germany, France.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Belgium, Germany, France.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Belgium, Germany, France.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd

Peter Goves; Nishay Patel

OTHER DISCLOSURES

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Belgium. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citiVelocity.com.)

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of

the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines**

through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangkok, 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the

client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. Citi Research generally disseminates its research to the Firm's global institutional and retail clients via both proprietary (e.g., Citi Velocity and Citi Personal Wealth Management) and non-proprietary electronic distribution platforms. Certain research may be disseminated only via Citi's proprietary distribution platforms; however such research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the author's previously published research. Certain research is made available only to institutional investors to satisfy regulatory requirements. Individual Citi Research analysts may also opt to circulate published research to one or more clients by email; such email distribution is discretionary and is done only after the research has been disseminated.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
